← Back to Home

How Does the Cochlea Tune for High and Low Frequencies? New MYO7A Isoform Reveals a Mechanism of Hereditary Hearing Loss

Researchers discovered a previously unreported MYO7A protein isoform in auditory hair cells and analyzed its relationship to frequency specialization in the mouse cochlea. The findings provide a more precise targeting map for gene therapy for Usher syndrome, but have not yet shown that hearing or vision can be restored.

By SURL BioNews

The cochlea does more than receive sound; it also functions like a precision tuner organized by frequency, with hair cells in different locations responding to high or low frequencies. When mutations occur in the MYO7A gene, which maintains this mechanical sensory system, patients may have hearing impairment from birth and subsequently experience progressive vision loss. A mouse study now shows that MYO7A, previously regarded as having a single role, actually includes functionally distinct protein isoforms distributed in separate regions along the cochlea.

Published in *Nature Communications*, the study was conducted by teams from the University of Virginia, the University of Florida, and the University of Colorado Anschutz Medical Campus. Using long-read RNA sequencing, the researchers identified MYO7A-N, a previously unreported isoform, in addition to the known canonical isoform MYO7A-C. Both are located at the upper insertion site of the hair-cell stereocilia's “tip links,” structures that convert tiny sound-induced displacements into electrical signals.

More importantly, the two isoforms are not distributed uniformly. Inner hair cells primarily express MYO7A-C, while outer hair cells contain both isoforms, which form opposing concentration gradients along the cochlea. MYO7A-N is more abundant at the cochlear base, which detects high-frequency sounds, and gradually decreases toward the apex, which detects low frequencies. Based on this pattern, the research team proposed that the ratio of the isoforms may regulate tip-link tension, helping hair cells calibrate their sensitivity and frequency-resolution capacity.

In mice with MYO7A-N specifically knocked out, outer hair cells progressively degenerated, and the animals developed progressive hearing loss. Cryo-electron microscopy further showed that although the motor domains of MYO7A-N and MYO7A-C are broadly similar, they differ in local structure and at the actin interface. ATPase measurements also showed that the two have different catalytic activities. These results connect gene transcription, protein structure, and auditory phenotype into a possible mechanistic chain.

MYO7A mutations can cause Usher syndrome type 1B and some forms of nonsyndromic deafness. The study's therapeutic significance is that if MYO7A is restored using a gene vector in the future, it may not be sufficient to consider only a single universal version; hair-cell type, cochlear location, and isoform ratio may also need to be taken into account. In 2026, the United States approved a gene therapy targeting OTOF, another gene that causes deafness, demonstrating the clinical feasibility of delivering a therapeutic vector directly into the inner ear. However, the cellular division of labor and protein regulation involving MYO7A are clearly more complex.

These findings remain mechanistic research rather than validation of a therapy. The experiments were based primarily on genetically modified mice, ex vivo structural analyses, and enzyme measurements. The researchers have not yet demonstrated any MYO7A gene therapy vector, nor have they shown that restoring a specific isoform can prevent or reverse hearing loss. Whether the distribution pattern in the mouse cochlea fully corresponds to that in humans, and how early treatment would need to begin before hair cells are damaged, remain unanswered.

In addition, Usher syndrome also involves retinal degeneration. This study focused on auditory hair cells, so it cannot be used to infer that the same strategy could preserve vision. Its real advance is to give future therapy designers a clearer understanding of which protein should be restored, which cells it should be delivered to, and how to avoid disrupting the cochlea's existing precision tuning while repairing the gene.

References

  1. University of Florida McKnight Brain Institute
  2. Nature Communications
  3. PubMed, U.S. National Library of Medicine